InMed Pharmaceuticals Inc INM Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$15.56 up $2.35, 17.79% at close Nov 6
Last close · Previous close $13.21
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$15.56up $2.26, 16.99%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$13.21Nov 5
- Volume27.15KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume9.36KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $5.75 to $23.30; now $15.56
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
INM beat the S&P 500 in 3 of 7 periods.
| Period | INM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | INM: up 17.0% S&P 500: down 5.6% | INM beat the S&P 500 by 22.6 percentage points Beat |
| 3M | INM: up 8.8% S&P 500: down 4.1% | INM beat the S&P 500 by 12.9 percentage points Beat |
| YTD | INM: up 46.8% S&P 500: up 8.7% | INM beat the S&P 500 by 38.1 percentage points Beat |
| 1Y | INM: down 8.7% S&P 500: up 10.9% | INM trailed the S&P 500 by 19.6 percentage points Trailed |
| Long term | ||
| 3Y | INM: down 81.9% S&P 500: up 75.0% −43.4% vs +20.5% a year | INM trailed the S&P 500 by 156.9 percentage points Trailed |
| 5Y | INM: down 99.8% S&P 500: up 67.8% −70.8% vs +10.9% a year | INM trailed the S&P 500 by 167.6 percentage points Trailed |
| 10Y | INM: down 99.9% S&P 500: up 313.1% −51.1% vs +15.2% a year | INM trailed the S&P 500 by 413.0 percentage points Trailed |
$10,000 invested in INM 10 years ago (Nov 4, 2016) would be worth about $8 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
INM beat the S&P 500 in 3 of 7 periods.
| Period | INM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | INM: up 17.0% S&P 500: down 5.6% | INM beat the S&P 500 by 22.6 percentage points Beat |
| 3M | INM: up 8.8% S&P 500: down 4.3% | INM beat the S&P 500 by 13.1 percentage points Beat |
| YTD | INM: up 46.8% S&P 500: up 7.8% | INM beat the S&P 500 by 39.0 percentage points Beat |
| 1Y | INM: down 8.7% S&P 500: up 9.7% | INM trailed the S&P 500 by 18.4 percentage points Trailed |
| Long term | ||
| 3Y | INM: down 81.9% S&P 500: up 68.8% −43.4% vs +19.1% a year | INM trailed the S&P 500 by 150.7 percentage points Trailed |
| 5Y | INM: down 99.8% S&P 500: up 56.9% −70.8% vs +9.4% a year | INM trailed the S&P 500 by 156.7 percentage points Trailed |
| 10Y | INM: down 99.9% S&P 500: up 252.6% −51.1% vs +13.4% a year | INM trailed the S&P 500 by 352.5 percentage points Trailed |
$10,000 invested in INM 10 years ago (Nov 4, 2016) would be worth about $8 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$311,850.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since May 5, 2014.
Stock splits
4
Latest: 1-for-10 on . Share counts adjust after each split.
All 4 splits
- 1-for-10
- 1-for-20
- 1-for-25
- 1-for-33
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.94Mdown 18.3%
- Net income
- −$12.56M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY25 (Sep 30, 2024) | $1.26M | −$1.68M | Paused See the note under the price. |
| Q2 FY25 (Dec 31, 2024) | $1.11M | −$2.58M | Paused See the note under the price. |
| Q3 FY25 (Mar 31, 2025) | $0.00 | −$2.12M | Paused See the note under the price. |
| Q4 FY25 (Jun 30, 2025) | $0.00 | −$1.79M | Paused See the note under the price. |
| Q1 FY26 (Sep 30, 2025) | $1.12M | −$1.73M | Paused See the note under the price. |
| Q2 FY26 (Dec 31, 2025) | $820.19K | −$2.03M | Paused See the note under the price. |
| Q3 FY26 (Mar 31, 2026) | $0.00 | −$2.97M | Paused See the note under the price. |
| Q4 FY26 (Jun 30, 2026) | $0.00 | −$5.84M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Jun 30, 2022) | $1.09M | −$18.60M | Paused See the note under the price. |
| FY23 (Jun 30, 2023) | $4.14M | −$7.95M | Paused See the note under the price. |
| FY24 (Jun 30, 2024) | $4.60M | −$7.68M | Paused See the note under the price. |
| FY25 (Jun 30, 2025) | $0.00 | −$8.16M | Paused See the note under the price. |
| FY26 (Jun 30, 2026) | $0.00 | −$12.56M | Paused See the note under the price. |
Margins
- Gross 30.3%
- Operating −596.1%
- Net −647.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$8.64MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$8.64MLast 12 months
- Capital spending$0.00Last 12 months
- −445.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $231.68KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $2.23MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$2.23MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 1.37As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −172.4%Last 12 months
Over the last 12 months, InMed Pharmaceuticals lost money: its net loss was 172.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −136.8%Last 12 months
Over the last 12 months, InMed Pharmaceuticals’s net loss was 136.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About InMed Pharmaceuticals Inc
InMed Pharmac
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- British Columbia, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
INM news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
INM stock FAQ
What is INM stock’s price today?
InMed Pharmaceuticals (INM) traded at $15.56 at the close on , up $2.35 (17.79%) from the previous close of $13.21. Over the past 52 weeks it has traded between $5.75 and $23.30.
If you invested $1,000 in INM 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in INM on would be worth about $1 at the close on , a total return of −99.9%. The same $1,000 would be worth $2 if invested five years ago and $913 if invested one year ago. Past performance doesn’t predict future returns.
How much revenue does InMed Pharmaceuticals make?
InMed Pharmaceuticals reported $1.9 million of revenue over the four quarters to , down 18.3% from the twelve months before. In its latest quarter (Q4 FY26, ended ) revenue was $0.0 thousand.
Is InMed Pharmaceuticals profitable?
Not over the four quarters to . InMed Pharmaceuticals reported a net loss of $12.6 million across those four quarters on $1.9 million of revenue.
Does INM pay a dividend?
InMed Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is INM’s 52-week high and low?
Over the past 52 weeks INM has traded as low as $5.75 and as high as $23.30. At $15.56 at the close on , it is 33.2% below that high and 170.6% above the low.
What is INM’s all-time high?
INM’s highest closing price was $311,850.00 on , adjusted for stock splits. At $15.56 at the close on , it is 100.0% below that record.
Has INM stock ever split?
Yes, four times: 1-for-33 on ; 1-for-25 on ; 1-for-20 on ; 1-for-10 on .
How has INM stock performed?
Including dividends and measured to the close on , INM has returned +46.8% so far this year and −8.7% over the past year, and −99.8% over five years (−70.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is InMed Pharmaceuticals in?
InMed Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in British Columbia, Canada.
What exchange does INM trade on?
InMed Pharmaceuticals trades on the Nasdaq under the ticker symbol INM. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.